HomeNewsBusinessEmbassy Parks REIT yields 14% returns, outperforms BSE realty index

Embassy Parks REIT yields 14% returns, outperforms BSE realty index

COVID-19 has slowed down launch activity, with global investors carefully watching the emerging work-from-home trend that may shrink office space requirements

July 06, 2020 / 14:09 IST
Story continues below Advertisement

In over a year since its launch, the Embassy Office Parks REIT has yielded 14 percent returns, which is higher than the returns generated by BSE Realty Index, which yielded negative returns of -20 percent in the same period, a report has said.

However, the COVID-19 outbreak has slowed down activity, with global investors carefully watching the emerging work-from-home trend that may shrink office space requirements.

Story continues below Advertisement

Developers worry about the attainable rental values for renewals and new leases, as there may be a demand slowdown in the short term. Commitments on future spaces, if withdrawn, may adversely impact the commercial office sector, according to property consultant Anarock.

Embassy Office Parks is still the only publicly-traded Indian REIT with a market capitalization of approximately 3.45 billion dollars or 17 percent of listed RE market capitalization in India, the report said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show